

## References

M-54

1. Farcas AD, Anton FP, Mocan M, Vida-Simiti LA. Hemodynamic monitoring using thoracic bioimpedance - An optimal solution for the treatment of hypertension. *Clujul Medical*. 2018;91(4):474-478.
2. Medina-Lezama J, Narvaez-Guerra O, Herrero-enriquez K, et. al. Hemodynamic patterns identified by impedance cardiography predict mortality in the general population: The PREVENCIÓN Study. *J. Am. Heart Assoc*. 2018;7(18).
3. Food and Drug Administration. Summary of Safety and Effectiveness Data (SSED): CardioMEMS HF System.2014; [https://www.accessdata.fda.gov/cdrh\\_docs/pdf10/P100045b.pdf](https://www.accessdata.fda.gov/cdrh_docs/pdf10/P100045b.pdf).
4. Leão R, Da Silvab P, Pocinhoa R, Alvesd M, Virellaf D, Reisb R. Good agreement between echocardiography and impedance cardiography in the assessment of left ventricular performance in hypertensive patients. 2018; 40(5): 461-467
5. Hayes, Inc. Hayes Technology Brief. *CARDIOMEMS IMPLANTABLE HEMODYNAMIC MONITOR (ABBOTT) FOR MANAGING PATIENTS WITH HEART FAILURE*. Landsdale, PA:Hayes,Inc;-July 2023.
6. Curtain JP, Lee MMY, McMurray JJ, Gardner RS, Petrie MC, Jhund PS. Efficacy of implantable haemodynamic monitoring in heart failure across ranges of ejection fraction: A systematic review and meta-analysis. *Heart*. 2023; 109(11):823-831.
7. Perl L, Meerkin D, D'amario D, et. al. VECTOR-HF Trial Investigators. The V-LAP System for Remote Left Atrial Pressure Monitoring of Patients With Heart Failure: Remote Left Atrial Pressure Monitoring. *J Card Fail*. 2022;28(6):963-972.
8. Abbott. CardioMEMS HF System. Education & training. 2022b. Available at: <https://www.cardiovascular.abbott/us/en/hcp/products/heart-failure/pulmonary-pressure-monitors/cardiomems/education-and-training.html>.
9. Abbott. CardioMEMS HF System. Strategies for practice management. 2022a. Available at: <https://www.cardiovascular.abbott/us/en/hcp/products/heart-failure/pulmonary-pressure-monitors/cardiomems/practice-management-workflow.html>.
10. Alcaraz A, Rojas-Roque C, Prina D, et al. Improving the monitoring of chronic heart failure in Argentina: Is the implantable pulmonary artery pressure with cardiomems heart failure system cost-effective? *Cost Eff Resour Alloc*. 2021;19(1):40.
11. Angermann CE, Assmus B, Anker SD, et al. Pulmonary artery pressure-guided therapy in ambulatory patients with symptomatic heart failure: The CardioMEMS European Monitoring Study for Heart Failure (MEMS-HF). *Eur J Heart Fail*. 2020;22(10):1891-1901.
12. Ayyadurai P, Alkhawam H, Saad M, et al. An update on the CardioMEMS pulmonary artery pressure sensor. *Ther Adv Cardiovasc Dis*. 2019;13:1753944719826826.
13. Boczor S, Daubmann A, Eisele M, Blozik E, Scherer M. Quality of life assessment in patients with heart failure: Validity of the German version of the generic EQ-5D-5L™. *BMC Public Health*. 2019;19(1):1464

14. Cowie MR, Flett A, Cowburn P, et al. Real-world evidence in a national health service: Results of the UK CardioMEMS HF System Post-market Study. *ESC Heart Fail.* 2022;9(1):48-56
15. Duque ER, Briasoulis A, Alvarez PA. Heart failure with preserved ejection fraction in the elderly: Pathophysiology, diagnostic and therapeutic approach. *J Geriatr Cardiol.* 2019;16(5):421-428.
16. Faragli A, Abawi D, Quinn C, et al. The role of non-invasive devices for the telemonitoring of heart failure patients. *Heart Fail Rev.* 2021;26(5):1063-1080.
17. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: a report of American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines [published correction appears in *Circulation.* May 3, 2022;145(18):e1033]. *Circulation.* 2022;145(18):e895-e1032
18. Joshi R, Nair A. The utility of CardioMEMS, a wireless hemodynamic monitoring system in reducing heart failure related hospital readmissions. *J Nurse Pract.* 2021;17(3):267-272
19. Kishino Y, Kuno T, Malik AH, et al. Effect of pulmonary artery pressure-guided therapy on heart failure readmission in a nationally representative cohort. *ESC Heart Fail.* 2022
20. Kotalczyk A, Imberti JF, Lip GYH, Wright DJ. Telemedical monitoring based on implantable devices-the evolution beyond the CardioMEMS™ technology. *Curr Heart Fail Rep.* 2022;19(1):7-14.
21. Lander MM, Aldweib N, Abraham WT. Wireless hemodynamic monitoring in patients with heart failure. *Curr Heart Fail Rep.* 2021;18(1):12-22.
22. Lindenfeld J, Abraham WT, Maisel A, et al. Hemodynamic-GUIDEd management of Heart Failure (GUIDE-HF). *Am Heart J.* 2019;214:18-27.
23. Lindenfeld J, Zile MR, Desai AS, et al. Haemodynamic-guided management of heart failure (GUIDE-HF): A randomised controlled trial. *Lancet.* 2021;398(10304):991-1001
24. McDonagh TA, Metra M, Adamo M, et al. Erratum: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J.* 2021;42(48):4901.
25. National Institute for Health and Care Excellence (NICE). Percutaneous implantation of pulmonary artery pressure sensors for monitoring treatment of chronic heart failure. Interventional Procedures Guidance No. IPG711. London, UK: National Institute for Health and Clinical Excellence; 2021.
26. Paz PA, Mantilla BD, Argueta EE, Mukherjee D. Narrative review: The holy grail: Update on pharmacotherapy for heart failure with preserved ejection fraction. *Ann Transl Med.* 2021;9(6):523.
27. Radhoe SP, Brugts JJ. CardioMEMS™: A tool for remote hemodynamic monitoring of chronic heart failure patients. *Future Cardiol.* 2022;18(3):173-183.

28. Shavelle DM, Desai AS, Abraham WT, et al. Lower rates of heart failure and all-cause hospitalizations during pulmonary artery pressure-guided therapy for ambulatory heart failure: One-year outcomes from the CardioMEMS post-approval study. *Circ Heart Fail.* 2020;13(8):e006863.
29. Spertus JA, Jones PG, Sandhu AT, Arnold SV. Interpreting the Kansas City Cardiomyopathy Questionnaire in clinical trials and clinical care: JACC state-of-the-art review. *J Am Coll Cardiol.* 2020;76(20):2379-2390.
30. Thakker RA, Abu-Jazar D, Cabello R, et al. Outcomes in hospitalization in patients with heart failure undergoing remote pulmonary artery pressure monitoring: A systematic review and meta-analysis of major trials. *Curr Probl Cardiol.* Epub ahead of print. September 20, 2021:100980.
31. Tsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke statistics-2022 update: A report from the American Heart Association. *Circulation.* 2022;145(8):e153-e639.
32. Veenis JF, Brugts JJ. Remote monitoring of chronic heart failure patients: Invasive versus non-invasive tools for optimising patient management. *Neth Heart J.* 2020;28(1):3-13.
33. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation.* 2022; 145(18): e895-e1032.
34. National Institute for Health and Care Excellence (NICE). Interventional procedures guidance: Percutaneous implantation of pulmonary artery pressure sensors for monitoring treatment of chronic heart failure [IPG711]. November 2021; <https://www.nice.org.uk/guidance/ipg711>. Accessed May 5, 2023
35. Krzesiński P, Jankowska EA, Siebert J, et al. Effects of an outpatient intervention comprising nurse-led non-invasive assessments, telemedicine support and remote cardiologists' decisions in patients with heart failure (AMULET study): a randomised controlled trial. *Eur J Heart Fail.* 2022; 24(3): 565-577.
36. Lin AL, Hu G, Dhruva SS, et al. Quantification of Device-Related Event Reports Associated With the CardioMEMS Heart Failure System. *Circ Cardiovasc Qual Outcomes.* 2022; 15(10): e009116.
37. Shavelle DM, Desai AS, Abraham WT, et al. Lower rates of heart failure and all-cause hospitalizations during pulmonary artery pressure-guided therapy for ambulatory heart failure: One-year outcomes from the CardioMEMS post-approval study. *Circ Heart Fail.* 2020; 13(8): e006863.
38. DeFilippis EM, Henderson J, Axsom KM, et al. Remote hemodynamic monitoring equally reduces heart failure hospitalizations in women and men in clinical practice: A sex-specific analysis of the cardiomems post-approval study. *Circ Heart Fail.* 2021; 14(6): e007892.
39. Lindenfeld J, Zile MR, Desai AS, et al. Haemodynamic-guided management of heart failure (GUIDE-HF): A randomised controlled trial. *Lancet.* 2021; 398(10304): 991-1001.
40. Zile MR, Desai AS, Costanzo MR, et al. The GUIDE-HF trial of pulmonary artery pressure monitoring in heart failure: Impact of the COVID-19 pandemic. *Eur Heart J.* 2022; 43(27): 2603-2618.

41. Kishino Y, Kuno T, Malik AH, et al. Effect of pulmonary artery pressure-guided therapy on heart failure readmission in a nationally representative cohort. *ESC Heart Fail.* 2022; 9(4): 2511-2517.
42. Cowie MR, Flett A, Cowburn P, et al. Real-world evidence in a national health service: Results of the UK CardioMEMS HF System Post-Market Study. *ESC Heart Fail.* 2022; 9(1): 48-56.
43. Heywood JT, Zalawadiya S, Bourge RC, et al. Sustained Reduction in Pulmonary Artery Pressures and Hospitalizations During 2 Years of Ambulatory Monitoring. *J Card Fail.* 2023; 29(1): 56-66.
44. Angermann CE, Assmus B, Anker SD, et al. Pulmonary artery pressure-guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS European Monitoring Study for Heart Failure (MEMS-HF). *Eur J Heart Fail.* 2020; 22(10): 1891-1901.
45. Abraham J, Bharmi R, Jonsson O, et al. Association of Ambulatory Hemodynamic Monitoring of Heart Failure With Clinical Outcomes in a Concurrent Matched Cohort Analysis. *JAMA Cardiol.* 2019; 4(6): 556-563.
46. Assmus B, Angermann CE, Alkhout B, et al. Effects of remote haemodynamic-guided heart failure management in patients with different subtypes of pulmonary hypertension: Insights from the MEMS-HF study. *Eur J Heart Fail.* 2022; 24(12): 2320-2330.
47. Curtain JP, Lee MMY, McMurray JJ, et al. Efficacy of implantable haemodynamic monitoring in heart failure across ranges of ejection fraction: A systematic review and meta-analysis. *Heart.* 2023; 109(11): 823-831.
48. Burns DJP, Arora J, Okunade O, et al. International consortium for health outcomes measurement (ICHOM): Standardized patient-centered outcomes measurement set for heart failure patients. *JACC Heart Fail.* 2020; 8(3): 212-222.